ROCKVILLE, Md., Jan. 21 /PRNewswire-FirstCall/ — Neuralstem, Inc. (NYSE Amex: CUR) announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig’s disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.
“The treatment of the first patient with our spinal cord stem cells represents a significant milestone for the Company,” said Neuralstem President and CEO, Richard Garr.
Click here for complete article.